%0 Journal Article
%T Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers.
%A Matuszczak M
%A Kiljańczyk A
%A Marciniak W
%A Derkacz R
%A Stempa K
%A Baszuk P
%A Bryśkiewicz M
%A Sun P
%A Cheriyan A
%A Cybulski C
%A Dębniak T
%A Gronwald J
%A Huzarski T
%A Lener MR
%A Jakubowska A
%A Szwiec M
%A Stawicka-Niełacna M
%A Godlewski D
%A Prusaczyk A
%A Jasiewicz A
%A Kluz T
%A Tomiczek-Szwiec J
%A Kilar-Kobierzycka E
%A Siołek M
%A Wiśniowski R
%A Posmyk R
%A Jarkiewicz-Tretyn J
%A Scott RJ
%A Narod SA
%A Lubiński J
%J Antioxidants (Basel)
%V 13
%N 5
%D 2024 May 16
%M 38790714
%F 7.675
%R 10.3390/antiox13050609
%X BRCA1 mutations predispose women to breast and ovarian cancer. The anticancer effect of zinc is typically linked to its antioxidant abilities and protecting cells against oxidative stress. Zinc regulates key processes in cancer development, including DNA repair, gene expression, and apoptosis. We took a blood sample from 989 female BRCA1 mutation carriers who were initially unaffected by cancer and followed them for a mean of 7.5 years thereafter. There were 172 incident cases of cancer, including 121 cases of breast cancer, 29 cases of ovarian cancers, and 22 cancers at other sites. A zinc level in the lowest tertile was associated with a modestly higher risk of ovarian cancer compared to women with zinc levels in the upper two tertiles (HR = 1.65; 95% CI 0.80 to 3.44; p = 0.18), but this was not significant. Among those women with zinc levels in the lowest tertile, the 10-year cumulative risk of ovarian cancer was 6.1%. Among those in the top two tertiles of zinc level, the ten-year cumulative risk of ovarian cancer was 4.7%. There was no significant association between zinc level and breast cancer risk. Our preliminary study does not support an association between serum zinc level and cancer risk in BRCA1 mutation carriers.